Hui Wang, M.D.

Shenzhen Municipal Third Hospital, China

Disclosure(s): No financial relationships to disclose

Poster(s):

• (P-587) Durable Virological Suppression, Reduced Body Weight, and Improved Serum Cholesterol after Switch to Tenofovir DF-Containing, Ainuovirine-Based Antiretroviral Regimen in People with HIV-1: the 96-Week Results of the SPRINT Trial, a Randomized, Active-Controlled Phase 3 Extensional Study
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-588) Improved Lipid Profile in Virologically Suppressed People with HIV-1 Switching to Tenofovir DF-Containing, Ainuovirine-Based Compared to Tenofovir Alafenamide-Containing, Boosted Elvitegravir-Based Antiretroviral Regimen: the Secondary Analyses of 48-Week Results of the SPRINT Trial, a Randomized, Active-Controlled Phase 3 Study
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT

• (P-589) Cholesterol Control in Virologically Suppressed People with HIV-1 Switching to Tenofovir DF-containing, Ainuovirine-Based Compared to Tenofovir Alafenamide-Containing, Boosted Elvitegravir-Based Antiretroviral Regimen: Hypercholesterolemic Subgroup Analyses of the SPRINT Trial, a Randomized, Active-Controlled Phase 3 Study
  Thursday, October 17, 2024

  12:15 PM – 1:30 PM US PT